This article is more than 5 years old. Information may no longer be current.
Study: Ocriplasmin treatment closed full-thickness macular holes in some patients
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — A single-dose injection of ocriplasmin was able to close full-thickness macular holes in 41% of patients, according to a subgroup analysis of the MIVI-TRUST phase 3 clinical trial presented here.
Dante J. Pieramici, MD, and David S. Boyer, MD, presented results of the subgroup analysis in a poster presentation at the Association for Research in Vision and Ophthalmology meeting.
In the study, 106 eyes with a full-thickness macular hole were randomized to receive a 125-µg injection of ocriplasmin (ThromboGenics) and 47 eyes received placebo.
"At day 28, 40.6% of ocriplasmin-treated eyes demonstrated nonsurgical full-thickness macular hole closure as compared to 10.6% of placebo-treated eyes," the authors said in the poster. At 6 months, the same percentage of macular holes remained closed.
Patients tolerated treatment well, and ocriplasmin did not interfere with vitrectomy results in closing remaining macular holes, according to the poster.
- Disclosure: Dr. Pieramici Boyer receives financial support, is a consultant with and receives other reimbursements from Genentech and Thrombogenics; receives financial support from Regeneron ; and is a consultant with and receives other reimbursements from Alimera. Dr. Boyer receives financial support, is a consultant with and receives other reimbursements from Alcon, Allergan, Genentech and Regeneron. He is a consultant with Allegro, Neurotech and Novartis/QLT. He receives financial support from iCo. He receivers other reimbursements from Novartis and Pfizer.